{"id":"W4232494473","doi":"10.1182/blood-2019-123486","title":"Randomized Phase 2 Study of Subcutaneous Daratumumab Plus Carfilzomib/Dexamethasone Versus Carfilzomib/Dexamethasone Alone in Patients with Multiple Myeloma Who Have Been Previously Treated with Intravenous Daratumumab to Evaluate Retreatment (LYNX)","year":2019,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"ca_institutions":"Institute of Cancer Research; University of Calgary","funders":"","keywords":"Daratumumab; Medicine; Carfilzomib; Dexamethasone; Internal medicine; Multiple myeloma; Oncology; Adverse effect; Surgery; Proteasome inhibitor; Bortezomib","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003018664,0.00296135,0.004228715,0.0006687348,0.0006314829,0.001537694,0.001331891,0.002330385,0.01080803],"category_scores_gemma":[0.00244398,0.001258392,0.002183761,0.0005225213,0.001799874,0.001684445,0.0006931152,0.004770203,0.002044074],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001323055,"about_ca_system_score_gemma":0.002376375,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001069582,"about_ca_topic_score_gemma":0.002155758,"domain_scores_codex":[0.9989527,0.0005207112,0.00004493379,0.0002106899,0.00008003617,0.0001908729],"domain_scores_gemma":[0.9981888,0.0003702723,0.0003604831,0.0001697821,0.0001139911,0.0007967514],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9727728,0.01741236,0.000595927,0.0001467098,0.0003566142,0.00004260035,0.00003367524,0.0002743764,0.002180187,0.00006725474,0.000518579,0.005598937],"study_design_scores_gemma":[0.8940136,0.1036108,0.0009881234,0.000008887306,0.0001605545,0.0000311134,0.0000118302,0.0003179445,0.0002709749,0.00008858633,0.0004873346,0.00001021863],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9755258,0.001637292,0.001135459,0.001132574,0.0009312193,0.0151813,0.001986847,0.0001958683,0.002273656],"genre_scores_gemma":[0.9598637,0.001504542,0.004353087,0.002955515,0.001147085,0.02044534,0.003356142,0.00006388115,0.006310597],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01080803,"threshold_uncertainty_score":0.03615642,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01949929881675953,"score_gpt":0.2947767710423797,"score_spread":0.2752774722256202,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}